Alta Sciences

APRIL 17, 2024

Five Promising Treatment Areas in Early-Phase Drug Development in 2024 aasimakopoulos Wed, 04/17/2024 - 15:52 Early-phase drug development is an ever-changing landscape, as emerging science leads to new promising areas of research for the treatment of human health issues.

Drug Development 52

Drug Development Treatment FDA Approval Drugs 52

DrugBank

JULY 24, 2024

This was the first successful drug development against a transcription factor, opening the door to targeting a whole new class of previously unreachable targets. The Promise of Multispecific Drugs The future of drug discovery looks even brighter with the development of multispecific drugs.

Small Molecule 98

Small Molecule Drugs Clinical Trials Therapies 98

Conversations in Drug Development Trends

AUGUST 14, 2024

A few notable developments include: Liquid Biopsy Technologies Liquid biopsy technologies involve analyzing biomarkers from bodily fluids to detect and monitor cancers, offering a non-invasive alternative to traditional biopsies. Proteomics Proteomics involves studying the entire set of proteins expressed in a cell or tissue.

Treatment 78

Treatment Therapies Disease Protein Expression 78

Drug Target Review

SEPTEMBER 10, 2024

The current landscape of protein drug development is characterised by accelerated timelines where new drugs are approved in months rather than years. Hence, in many cases an earlier IND may be prevented by the timely provision of representative Drug Substance (DS) to execute such toxicology studies.

Drug Development 64

Drug Development Clinical Supply Production FDA 64

Drug Target Review

JANUARY 20, 2025

The oncology drug development landscape is evolving rapidly, driven by the deployment of targeted therapies in precision medicine and regulatory initiatives like the FDAs Project Optimus. It also covers strategies for drug developers who have yet to identify a biomarker, helping them advance their programs effectively.

Clinical Trials 52

Clinical Trials Trials Drugs Drug Development 52

Conversations in Drug Development Trends

APRIL 7, 2025

Making strategic decisions when designing the protocol, such as including biomarkers like programmed death ligand-1 protein expression to guide the use of immune checkpoint inhibitors during treatment, can better assure safety and efficacy.

Research 40

Research Clinical Trials Trials Clinical Research 40